New Delhi, Aug. 25 -- Two Indian drugmakers have filed lawsuits against Danish drugmaker Novo Nordisk over its blockbuster weight-loss drug semaglutide, which is set to lose its patent in India in March 2026. With just about six months to go, why are these companies pursuing lawsuits against the innovator? Mint explains.

Last week, Natco Pharma filed six lawsuits in the Delhi High Court against Danish drugmaker Novo Nordisk for its popular anti-obesity drug semaglutide, sold as Wegovy in India. The Hyderabad-based drugmaker contended that its versions of semaglutide and the delivery device do not infringe on Novo Nordisk's patented drug or devices, meaning it could launch them even before the patent expires.

Natco had issued notices to ...